Immunophenotypic Analysis of AIDS-Related Diffuse Large B-Cell Lymphoma and Clinical Implications in Patients

Abstract Diffuse large B-cell lymphoma (DLBCL) represents a clinically heterogeneous disease. Models based on immunohistochemistry predict clinical outcomes. However, whether these immunophenotypes could be applied as a predictive indicator in AIDS-Related DLBCL remains unclear. To explore predictive immunophenotypes and their clinical implications in AIDS-related DLBCL, we analyzed patient samples treated 2008–2019 with R-CHOP/CHOP-like and central nervous system (CNS) prevention treatment for DLBCL with HIV infection in Chongqing cancer hospital. c-MYC, CD4 count, and co-expression of BCL-2 and c-MYC presented the potential of being predictive markers in the prognosis of AIDS-related DLBCL, while absolute lymphocyte count did not show any effects in clinical outcomes. Surprisingly, we found that BCL-2 and the germinal center b-cell (GCB) subtype also could predict the prognosis of AIDS-related DLBCL, which against previous studies. Thus, the specific mechanism of BCL-2 and GCB subtype in AIDS-related DLBCL still requires to be explored.